Cue Biopharma Inc

Cue Biopharma is a biopharmaceutical company engaged in designing and developing a proprietary class of biologic product candidates engineered to selectively modulate the human immune system. The company's Immuno-STAT? (Selective Targeting and Alteration of T Cells) platform enables the company to engineer product candidates that it calls Immuno-STATs? or Immuno-STAT biologics? that directly engage with and direct the activity of antigen specific T cells in a patient's body through a singular molecular framework.
  • TickerCUE
  • ISINUS22978P1066
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ...

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. During the fireside chat, Cue Biopharma will provide an update highlighting the ongoing Phase 1a/1b monotherapy dose esca...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . Members of the Cue Biopharma executive management team will provide a clinic...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Confer...

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the on February 25, 2021. Presentation DetailsTitle: Next Generation Synthetic VaccinesImmuno-STA...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senio...

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today it has appointed Dr. Matteo Levisetti ...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in ...

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ...

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. During the fireside chat, Cue Biopharma will provide an update highlighting the ongoing Phase 1a/1b monotherapy dose esca...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . Members of the Cue Biopharma executive management team will provide a clinic...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Confer...

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the on February 25, 2021. Presentation DetailsTitle: Next Generation Synthetic VaccinesImmuno-STA...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senio...

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today it has appointed Dr. Matteo Levisetti ...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in ...

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ...

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. During the fireside chat, Cue Biopharma will provide an update highlighting the ongoing Phase 1a/1b monotherapy dose esca...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . Members of the Cue Biopharma executive management team will provide a clinic...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Confer...

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the on February 25, 2021. Presentation DetailsTitle: Next Generation Synthetic VaccinesImmuno-STA...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senio...

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today it has appointed Dr. Matteo Levisetti ...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in ...

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ...

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. During the fireside chat, Cue Biopharma will provide an update highlighting the ongoing Phase 1a/1b monotherapy dose esca...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . Members of the Cue Biopharma executive management team will provide a clinic...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Confer...

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the on February 25, 2021. Presentation DetailsTitle: Next Generation Synthetic VaccinesImmuno-STA...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senio...

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today it has appointed Dr. Matteo Levisetti ...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in ...

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences ...

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 16-17, 2021. During the fireside chat, Cue Biopharma will provide an update highlighting the ongoing Phase 1a/1b monotherapy dose esca...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Host Business Update Call and Webcast

Cue Biopharma to Host Business Update Call and Webcast CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will host a conference call and webcast to provide a business update on Monday, May 17, 2021 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s . Members of the Cue Biopharma executive management team will provide a clinic...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Confer...

Cue Biopharma to Present at the 7th Annual Immuno-Oncology 360° Conference CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the on February 25, 2021. Presentation DetailsTitle: Next Generation Synthetic VaccinesImmuno-STA...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senio...

Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today it has appointed Dr. Matteo Levisetti ...

 PRESS RELEASE
CUE Cue Biopharma I... (Health Care)

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in ...

Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA® (pembrolizumab) as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that on February 1, 2021, the first patient was dosed in a Phase 1 dose escalation clinical trial of CUE-101 in combination with Merck’s anti-...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch